Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

New-onset psychosis following androgen deprivation therapy for prostate cancer.

Bernad DM, Dal Pra A, Baule C, Frey BN, Faria S.

Can J Urol. 2013 Aug;20(4):6868-70.

PMID:
23930615
2.

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.

Merseburger AS, Hupe MC.

Adv Ther. 2016 Jul;33(7):1072-93. doi: 10.1007/s12325-016-0351-4. Epub 2016 May 31. Review.

3.

[Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].

Salvador C, Planas J, Raventós C, Ropero J, Placer J, López MA, Morote J.

Actas Urol Esp. 2012 Apr;36(4):205-9. doi: 10.1016/j.acuro.2011.09.006. Epub 2011 Dec 16. Spanish.

PMID:
22178349
4.

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.

Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi: 10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23. Review.

PMID:
23092636
5.

Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.

Walker LM, Tran S, Robinson JW.

Clin Genitourin Cancer. 2013 Dec;11(4):375-84. doi: 10.1016/j.clgc.2013.05.004. Epub 2013 Jul 25. Review.

PMID:
23891497
6.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

7.

Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.

Clinton TN, Woldu SL, Raj GV.

Expert Opin Pharmacother. 2017 Jun;18(8):825-832. doi: 10.1080/14656566.2017.1328056. Epub 2017 May 19. Review.

PMID:
28480768
8.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
10.

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ.

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1.

PMID:
21807761
11.

Prostate cancer, osteoporosis and fracture risk.

Allain TJ.

Gerontology. 2006;52(2):107-10. Review.

PMID:
16508318
12.

Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.

Lu L, Peters J, Roome C, Stein K.

BJU Int. 2012 Apr;109(8):1183-92. doi: 10.1111/j.1464-410X.2011.10434.x. Epub 2011 Aug 23.

13.

A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.

Yamaguchi Y, Hayashi Y, Ishizuya Y, Takeda K, Nakai Y, Arai Y, Nakayama M, Kakimoto K, Nishimura K.

Jpn J Clin Oncol. 2015 Feb;45(2):197-201. doi: 10.1093/jjco/hyu186. Epub 2014 Nov 7.

PMID:
25381383
14.

Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.

Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA, Morote J.

Urol Int. 2013;90(1):41-4. doi: 10.1159/000342814. Epub 2012 Dec 12.

PMID:
23235105
15.

Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.

Kirby RS, Fitzpatrick JM, Clarke N.

BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. Review.

16.

Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.

Harrington JM, Schwenke DC, Epstein DR, Bailey DE Jr.

Oncol Nurs Forum. 2014 Jan 1;41(1):21-9. doi: 10.1188/14.ONF.21-29.

17.

Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.

Greiman AK, Keane TE.

Curr Urol Rep. 2017 Jun;18(6):41. doi: 10.1007/s11934-017-0688-5. Review.

PMID:
28417429
18.

Landmarks in hormonal therapy for prostate cancer.

Hammerer P, Madersbacher S.

BJU Int. 2012 Oct;110 Suppl 1:23-9. doi: 10.1111/j.1464-410X.2012.11431.x. Review.

19.

Pharmacotherapy for prostate cancer: the role of hormonal treatment.

Shahani R, Fleshner NE, Zlotta AR.

Discov Med. 2007 Aug;7(39):118-24.

20.

Is the flare phenomenon clinically significant?

Bubley GJ.

Urology. 2001 Aug;58(2 Suppl 1):5-9. Review.

PMID:
11502435

Supplemental Content

Support Center